VanEck 1-3 Month US Treasury Bond ETF (TBIL) |
Financials |
$142 |
Final Dividend/Distribution for period ending 31 Oct 2024
|
31 Oct 2024 8:36AM |
$51.260 |
$51.630 |
risen by
0.72%
|
|
VanEck Australian Corporate Bond Plus ETF (PLUS) |
Financials |
$409 |
Final Dividend/Distribution for period ending 31 Oct 2024
|
31 Oct 2024 8:36AM |
$16.750 |
$17.380 |
risen by
3.76%
|
|
VanEck 10+ Year Australian Government Bond ETF (XGOV) |
Financials |
$341 |
Final Dividend/Distribution for period ending 31 Oct 2024
|
31 Oct 2024 8:36AM |
$50.570 |
$52.690 |
risen by
4.19%
|
|
VanEck Emerging Income Opportunities Active ETF (Managed Fund) (EBND) |
Financials |
$217 |
Final Dividend/Distribution for period ending 31 Oct 2024
|
31 Oct 2024 8:36AM |
$10.380 |
$10.960 |
risen by
5.59%
|
|
VanEck Global Listed Private Credit (AUD Hedged) ETF (LEND) |
Financials |
$238 |
Final Dividend/Distribution for period ending 31 Oct 2024
|
31 Oct 2024 8:36AM |
$19.660 |
$16.830 |
fallen by
14.39%
|
|
Fat Prophets Global Contrarian Fund Limited (FPC) ORDINARY FULLY PAID |
Financials |
$43 |
Update - Notification of buy-back - FPC
|
31 Oct 2024 8:36AM |
$0.975 |
$1.520 |
risen by
55.90%
|
|
Champion Iron Limited (CIA) ORDINARY FULLY PAID |
Materials |
$2,597 |
Dividend/Distribution - CIA
|
31 Oct 2024 8:35AM |
$5.890 |
$4.870 |
fallen by
17.32%
|
|
Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$30,936 |
Update on Coles Supply Chain Modernisation
|
31 Oct 2024 8:35AM |
$17.700 |
$23.050 |
risen by
30.23%
|
|
Catapult Sports Ltd (CAT) ORDINARY FULLY PAID |
Information Technology |
$2,071 |
Date of 1H FY25 Results, Briefing
|
31 Oct 2024 8:35AM |
$2.500 |
$7.300 |
risen by
192%
|
|
Bisalloy Steel Group Limited (BIS) ORDINARY FULLY PAID |
Materials |
$271 |
Letter to Shareholders Change of 2024 AGM to virtual
|
31 Oct 2024 8:34AM |
$3.500 |
$5.640 |
risen by
61.14%
|
|
Eureka Group Holdings Limited (EGH) ORDINARY FULLY PAID |
Real Estate |
$226 |
Retail Offer Booklet
|
31 Oct 2024 8:34AM |
$0.635 |
$0.530 |
fallen by
16.54%
|
|
EGH - Price-sensitive ASX Announcement
Full Release
Key Points
- Eureka to acquire 441 units across 7 villages and 38 single units.
- Total expected investment for acquisitions is $49.9 million.
- Fully underwritten equity raising of $70.4 million announced.
- Equity raising consists of a $55.4 million entitlement offer and a $15 million institutional placement.
- FY25 guidance includes at least 16% growth in underlying EBITDA.
- FY25 underlying EPS is expected to grow by at least 8%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Elixir Energy Limited (EXR) ORDINARY FULLY PAID |
Energy |
$63 |
Quarterly Activities Report and Appendix 5B Sept 2024
|
31 Oct 2024 8:33AM |
$0.057 |
$0.045 |
fallen by
21.05%
|
|
EXR - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful stimulation and flow testing of the Daydream-2 appraisal well.
- Gas flowed from multiple stimulated zones, including deep coals.
- ATP 2077 was formally awarded, adding 175 Bcf of additional contingent resources.
- Elixir's financial position remains strong with $10 million cash at quarter end.
- Ongoing production testing at the Nomgon Pilot Project in Mongolia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Vinyl Group Ltd (VNL) ORDINARY FULLY PAID |
Information Technology |
$122 |
Application for quotation of securities - VNL
|
31 Oct 2024 8:33AM |
$0.145 |
$0.090 |
fallen by
37.93%
|
|
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID |
Health Care |
$10 |
Quarterly Activities Report and Appendix 4C
|
31 Oct 2024 8:33AM |
$0.081 |
$0.009 |
fallen by
88.89%
|
|
PER - Price-sensitive ASX Announcement
Full Release
Key Points
- Avicursen (ATL 1102) shows preclinical activity in autoimmune epilepsy.
- Nine-month animal toxicology study shows no unexpected findings.
- Phase IIb clinical trial of avicursen for Duchenne muscular dystrophy on track for December 2024 data readout.
- Oversubscribed institutional placement raised $13 million.
- Company funded into CY26 based on current forecast activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Resource Development Group Limited (RDG) ORDINARY FULLY PAID |
Industrials |
$24 |
AGM Notice of Meeting and Notice Letter
|
31 Oct 2024 8:33AM |
$0.027 |
$0.008 |
fallen by
70.37%
|
|
Vinyl Group Ltd (VNL) ORDINARY FULLY PAID |
Information Technology |
$122 |
Cleansing Notice - Note and Option Conversion
|
31 Oct 2024 8:33AM |
$0.145 |
$0.090 |
fallen by
37.93%
|
|
Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$9,331 |
Update - Notification of buy-back - AFI
|
31 Oct 2024 8:32AM |
$7.450 |
$7.400 |
fallen by
0.67%
|
|
Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$30,936 |
2025 First Quarter Sales Results
|
31 Oct 2024 8:32AM |
$17.700 |
$23.050 |
risen by
30.23%
|
|
COL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total group sales revenue increased by 2.9% to $10,548 million.
- Supermarkets sales revenue rose by 3.5% to $9,507 million.
- eCommerce sales growth reached 22.4% in supermarkets.
- Inflation in supermarkets remained low at 1%, excluding tobacco.
- New product launches aimed at enhancing customer experience for the festive season.
- Focus on value campaigns and exclusive brands to attract customers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$169 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:32AM |
$0.200 |
$0.400 |
risen by
100%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 3 Protocol Submission was made to the US FDA on 29th October 2024.
- The FDA review period is expected to conclude on 28th November 2024.
- Adjustments to the trial design aim to improve patient convenience and trial efficiency.
- Paradigm anticipates a R&D incentive rebate of $5-6 million.
- The company reported a net cash outflow of $4.72 million for the September 2024 quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$420 |
Appendix 4C Cash Flow Report
|
31 Oct 2024 8:31AM |
$0.180 |
$0.275 |
risen by
52.78%
|
|
TTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash from operating activities was negative at $854,000.
- Cash and cash equivalents at the end of the quarter totaled $1,616,000.
- The company announced a $30 million capital raise.
- Tranche 1 of the capital raise raised $17.2 million.
- Tranche 2 is subject to shareholder approval.
- Payments to related parties amounted to $229,000.
- Estimated quarters of funding available is 1.9.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$420 |
Quarterly Activities Report Q1 FY2025
|
31 Oct 2024 8:31AM |
$0.180 |
$0.275 |
risen by
52.78%
|
|
TTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Leadership expansion with Jim Simpson appointed as U.S. President and new CEO effective January 2025
- Successful completion of AUD 30 million equity placement to fund U.S. operations
- FY2024 revenue grew by 127% to AUD 5.9 million with total orders reaching AUD 10 million
- Sales of cold spray systems to U.S. Navy and other defense partners totaling over AUD 1 million
- First D623 cold spray system sold in Australia for AUD 174,000
- Introduction of augmented reality solutions for cold spray technology
- Strategic focus on establishing a U.S.-based manufacturing facility
- Establishment of the Repkon Titomic joint venture with AUD 2.3 million order for TKF 1000 system
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$130 |
Bubs Q1 FY25 Quarterly Activity and Cashflow Statement
|
31 Oct 2024 8:30AM |
$0.125 |
$0.145 |
risen by
16%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- October 2024 group gross revenue of $11.8m, up ~121% on pcp.
- Q1 FY25 gross revenue of $24.2m, net revenue of $19.7m, slightly down 0.3% on pcp.
- Gross profit margin of 43% in Q1 FY25, up from 36% on pcp.
- Operating cash outflow of $4.9m in Q1 FY25.
- Bubs holds 55% of the domestic retail goat formula market.
- Total cash and cash equivalents of $14.3m available as of 30 September 2024.
- FDA approval for USA clinical trial expected in October 2025.
- FY25 outlook guidance reaffirmed at $102m net revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Variscan Mines Limited (VAR) ORDINARY FULLY PAID |
Materials |
$8 |
Notification regarding unquoted securities - VAR
|
31 Oct 2024 8:30AM |
$0.009 |
$0.007 |
fallen by
27.78%
|
|
Acrux Limited (ACR) ORDINARY FULLY PAID |
Health Care |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:29AM |
$0.053 |
$0.013 |
fallen by
75.47%
|
|
ACR - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approved Dapsone 7.5% Gel in August 2024.
- Launch target date for Dapsone 7.5% Gel is early 2025.
- Dapsone 5% Gel was launched in April 2024.
- Received $2.728 million from the Australian Tax Office for FY24 R&D Tax Incentive.
- Net cash outflows from operating activities totaled $2.234 million for the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Althea Group Holdings Limited (AGH) ORDINARY FULLY PAID |
Health Care |
$19 |
Q1FY25 Business Update Presentation
|
31 Oct 2024 8:29AM |
$0.040 |
$0.019 |
fallen by
52.50%
|
|
AGH - Price-sensitive ASX Announcement
Full Release
Key Points
- Record recreational cannabis revenue of $6.2 million.
- Total revenue guidance for FY25 refined to $50 million to $57 million.
- Divested MyAccess Clinics for $1.0 million, reducing costs by $1.5 million.
- New emulsion lab in Florida for cannabis-infused beverages.
- Ongoing discussions with new US customers to expand market reach.
- Positive operating cash flow of $304,000 supported by cost-saving initiatives.
- Pharmaceutical cannabis revenue of $2.1 million.
- Enhanced supplier agreements to improve gross margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.